Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infections

In brief

New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs. This study will test the safety and effectiveness of three different doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected patients.

Key facts

Study ID
NCT00082498
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
119
Starts
2004-05-01
Expected to finish
2011-01-01
Last updated by the study team
2021-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.